$46.66 $0.77 per serving
Product analysis
SAMe 400 mg offers a single-ingredient option with limited support for joint comfort. Its salt form alone does not confirm the stability or absorption of the preparations associated with that benefit.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
The SAMe salt form is identified, but its quality remains uncertain. The salt name alone does not establish stability or absorption.
Ingredient Transparency100
The active amount and salt form are stated. Those details help you compare the declared ingredient, although they do not describe every delivery feature.
Value For Money40
The price is less favorable for the declared active SAMe amount. A comparison based on active SAMe is more informative than tablet count alone.
Customer Satisfaction88
Customer ratings are generally positive. A very large number of responses gives a broad view of satisfaction.
Product Focus71
Joint comfort has some support, while everyday mood and stress benefits remain uncertain. The serving differs from the larger, coated preparations used for joint symptoms, and its normal liver-related role does not establish routine cleansing.
- Format
Tablet - Container
- 60 Tablet(s)
- Per serving
- $0.77
- Customer rating
- 4.6 · 10,658 ratings
Goals
Impact
High effect
SAMe · 400 mg
Impact
Moderate effect
SAMe · 400 mg
Impact
Highest effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
SAMe Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
SAMe (S-Adenosyl-L-Methionine Disulfate Tosylate) | 400 mg |
SAMe (S-Adenosyl-L-Methionine Disulfate Tosylate) · 400 mg OverallScore68
400 mg of SAMe per serving comes at a limited cost for the amount. A stabilized salt is indicated, though its specific form is unclear. Moisture protection from blister packaging is unclear. The active yield is unclear.
How this ingredient is rated
Active Ingredient Quality & Bioavailability77
A stabilized salt is indicated, but its specific form is unclear. Blister packaging is not documented, leaving moisture protection unclear.
Stabilized Salt Form
A stabilized salt is indicated, but its specific form is unclear.
Packaging Integrity
Blister packaging is not documented, leaving moisture protection unclear.
Dose, Safety & Label Transparency72
The serving lists 400 mg of SAMe. The information does not clarify how much of the listed amount is active SAMe rather than salt.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The information does not clarify how much of the listed amount is active SAMe rather than salt.
Value40
The cost for the listed SAMe amount is limited by uncertainty about protective release. Enteric coating or delayed release is not documented.
Price Per 400mg Active Dose
The cost for the listed SAMe amount is limited by uncertainty about protective release. Enteric coating or delayed release is not documented.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
- Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
- Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
- A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
- Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.